Is HQL or HTD more undervalued in 2026?

CirclFi compares TeklaLife Sciences Investors (HQL) and John Hancock Tax Advantaged Div (HTD) using 13 institutional-grade valuation models. HQL has a Quality of Company score of 1.9/10 while HTD scores 1.7/10.

Which is a better buy — HQL or HTD?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do HQL and HTD valuations compare?

HQL at $17.67 and HTD at $25.72 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

HQL vs HTD Valuation Comparison 2026 — Intrinsic Value Analysis

HQL

Asset Management

TeklaLife Sciences Investors

Quality

1.9

out of 10

Value Trap

—

Price

$17.67

Last close

Models

8/13

Active

HTD

Asset Management

John Hancock Tax Advantaged Div

Quality

1.7

out of 10

Value Trap

—

Price

$25.72

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	HQL Fair Value	HQL Upside	HTD Fair Value	HTD Upside
Bayesian DCF	Intrinsic	$4.68	-73.5%	$6.81	-73.5%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$71.50	+307.4%	$43.08	+66.6%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for HQL vs HTD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

HQL vs HTD — Which Stock Is More Undervalued?

HQL scores higher with a 1.9/10 quality rating vs HTD's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing TeklaLife Sciences Investors (HQL) and John Hancock Tax Advantaged Div (HTD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

HQL currently trades at $17.67 with a QOC of 1.9/10, while HTD trades at $25.72 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).